But in terms of sorting out that little piece, if a drug has been internationally approved--it's in the EU, Japan's got it, everything--is there a process by which stakeholders, patient groups, everybody, could fast-track that drug, based on international evidence, so that we could actually focus on the post-market piece in terms of real world life in Canada? I think Dr. Laupacis, or both of you, had said you want to do it in all jurisdictions.
On April 8th, 2008. See this statement in context.